{"id":501,"title":"[18F]FET PET enables histopathology-validated detection of non-contrast-enhancing glioblastoma","title_zh":"¹⁸F-FET PET 在组织病理学验证下检出非强化胶质母细胞瘤","url":"https://doi.org/10.1038/s41467-026-78980-1","doi":"10.1038/s41467-026-78980-1","pmid":null,"journal":"Nature Communications","kind":"paper","lang":"en","published_at":"2026-11-06T00:00:00+00:00","fetched_at":"2026-11-08T03:45:21+00:00","authors":["R. Stürzl","S. V. Kirchleitner","J. Lorenz","K. J. Schmidbauer","V. Stöcklein","S. Quach","L. Kaiser","S. Stöcklein","A. J. Zounek","E. Barci","I. von Polenz","J. Blobner","T. Greve","M. Brendel","P. Harter","V. C. Ruf","R. Rupprecht","F. Ringel","D. Kalasauskas","M. J. Riemenschneider","N. Thon","L. von Baumgarten","J-C Tonn","N. L. Albert"],"primary_topic":"art-clinical","topics":[{"slug":"art-clinical","score":4.0,"hits":["fet"]}],"topic_score":4.0,"preference_score":0.0,"preference_labels":[],"llm_score":22.0,"final_score":30.0,"score_dims":{"novelty":55,"rigor":78,"impact":10,"relevance":3,"translation":5},"recommend_reason":"该研究在神经肿瘤影像学领域设计严谨、样本与病理验证充分，但研究对象为胶质母细胞瘤，与生殖医学、辅助生殖及胚胎多组学无任何交集，不建议本领域读者投入时间。","keywords":["¹⁸F-FET PET","胶质母细胞瘤","氨基酸PET","增强MRI","组织病理学验证"],"selected":0,"story_id":null,"llm_provider":"deepseek","llm_model":"deepseek-flash","llm_effort":"low","source_key":"crossref-cns","source_name":"Crossref · CNS 与大子刊新上线（领域过滤）","source_tier":1,"mention_count":1,"has_interpretation":false,"journal_key":"nat-commun","journal_tier":"cns-sub","journal_if":14.7,"is_mock":false,"summary_zh":"该研究纳入 61 例 IDH 野生型胶质母细胞瘤患者，共 472 份组织样本，并以组织病理学作为验证标准，比较 O-(2-[¹⁸F]氟乙基)-L-酪氨酸 PET（[¹⁸F]FET PET）与增强 MRI 对肿瘤组织的显示能力。结果显示，[¹⁸F]FET PET 对肿瘤检出的敏感性显著更高（91.2% 对 52.6%），在 MRI 无强化区域仍保持较高阳性预测值（98.3%）；这些结果在初发与复发疾病、以及接受切除或活检的两组人群中均一致。作者认为，氨基酸 PET 可补充 MRI，揭示 MRI 难以显示的肿瘤负荷，并可能优化活检、切除与放疗规划。","summary":"Abstract Accurate visualization of glioblastoma is essential for guiding biopsy, resection and radiotherapy. Contrast-enhanced MRI is routine in clinical practice, yet it can miss metabolically active tumor outside areas of blood-brain barrier disruption. In a histopathology-validated cohort with 472 tissue samples of 61 patients with IDH-wildtype glioblastoma, we show that O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET ([ 18 F]FET PET) depicts tumor tissue significantly better than contrast-enhanced MRI (CE-MRI), especially in regions that show no enhancement on MRI. [ 18 F]FET PET achieves substantially higher sensitivity for tumor detection (91.2% vs 52.6%) and maintains high reliability in non-enhancing tissue (positive predictive value 98.3%), findings that are consistent across newly diagnosed and recurrent disease and in both cohorts undergoing either resection or biopsy. These results indicate that [ 18 F]FET PET complements MRI by revealing MRI-occult tumor burden. Incorporating amino acid PET into routine planning may therefore improve the accuracy of tumor visualization and, ultimately, patient management.","interpretation_basis":null,"fulltext_status":null,"interpretation":null,"fulltext":{"available":false,"status":null,"reason":"尚未抓取全文（未入选、分数未达阈值，或还没跑 fulltext 步骤）","pmcid":null,"license":null,"chars":0,"source":null,"fetched_at":null}}